ViroMed Co., Ltd. – Product Pipeline Review – H2 2011

ViroMed Co., Ltd. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “ViroMed Co., Ltd. - Product Pipeline Review - H2 2011” provides data on the ViroMed Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ViroMed Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from ViroMed Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• ViroMed Co., Ltd. - Brief ViroMed Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of ViroMed Co., Ltd. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of ViroMed Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the ViroMed Co., Ltd.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate ViroMed Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of ViroMed Co., Ltd. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the ViroMed Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with ViroMed Co., Ltd..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of ViroMed Co., Ltd. and identify potential opportunities in those areas.

Contents

ViroMed Co., Ltd. Snapshot
ViroMed Co., Ltd. Overview
Key Information
Key Facts
ViroMed Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
ViroMed Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ViroMed Co., Ltd. – Pipeline Products Glance
ViroMed Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ViroMed Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ViroMed Co., Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
ViroMed Co., Ltd. – Drug Profiles
PEG-VM501
PG 201
PG102
VM 505
VM202
VM206
VM501
ViroMed Co., Ltd. – Pipeline Analysis
ViroMed Co., Ltd. – Pipeline Products by Therapeutic Class
ViroMed Co., Ltd. – Pipeline Products by Route of Administration
ViroMed Co., Ltd. – Recent Pipeline Updates
ViroMed Co., Ltd. – Locations And Subsidiaries
Head Office
Company's Recent Developments
ViroMed Co., Ltd., Recent Developments
Oct 31, 2008: Korean FDA Approves Phase I Clinical Trial For VM202
Jun 30, 2008: China Approves Virmed's VM202 Clinical Trial For Peripheral Artery Disease
Oct 27, 2008: ViroMed Co., Ltd Completes First Clinical Trial In The US For VM202
Aug 27, 2008: Final Cohort Of ViroMed¡'s US Phase I Clinical Trial Of VM202 Begins
Oct 26, 2009: ViroMed Presents Results Of Multinational VM202 Trials At Cardiovascular Conference In China
Apr 22, 2010: ViroMed Submits Phase III Trial Application Of VM501 For Chemotherapy-Induced Thrombocytopenia In China
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
Sep 17, 2008: Spotlight On ViroMed¡'s CAD Gene-Therapeutic VM202 In The 1st Page Of The Prestigious Medical Journal Radiology
Oct 12, 2011: ViroMed’s VM202 Receives Phase II Approval For PAD In China
Apr 12, 2010: ViroMed’s VM202RY Receives Phase II Trial Approval For PAD In Korea
Mar 10, 2009: ViroMed Receives US FDA Approval Of Phase II Trial For VM202 To Treat Peripheral Artery Disease
Jun 09, 2009: Viromed Complets Phase I Trials Of VM202 In Chaina For Peripheral Artery Disease
Mar 06, 2009: ViroMed Receives Approval For Diabetic Neuropathy Phase I/II Trial
Jan 05, 2010: Formatech Selects ViroMed’s VM206 For Fillanthropy Program
Financial Deals Landscape
ViroMed Co., Ltd., Deals Summary
ViroMed Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
ViroMed Secures $5.7 Million In Venture Financing
Partnerships
Enlyton Enters Into Licensing Agreement With ViroMed
Yuhan Enters Into Agreement With ViroMed
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

ViroMed Co., Ltd., Key Information
ViroMed Co., Ltd., Key Facts
ViroMed Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
ViroMed Co., Ltd. – Pipeline by Stage of Development, H2 2011
ViroMed Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
ViroMed Co., Ltd. – Phase III, H2 2011
ViroMed Co., Ltd. - Phase II, H2 2011
ViroMed Co., Ltd. - Phase I, H2 2011
ViroMed Co., Ltd. – Pre-Clinical, H2 2011
ViroMed Co., Ltd. - Pipeline By Therapeutic Class, H2 2011
ViroMed Co., Ltd. – Pipeline By Route of Administration, H2 2011
ViroMed Co., Ltd. – Recent Pipeline Updates, H2 2011
ViroMed Co., Ltd., Deals Summary
ViroMed Secures $5.7 Million In Venture Financing
Enlyton Enters Into Licensing Agreement With ViroMed
Yuhan Enters Into Agreement With ViroMed

LIST OF FIGURES

ViroMed Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
ViroMed Co., Ltd. – Pipeline by Stage of Development, H2 2011
ViroMed Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
ViroMed Co., Ltd. – Pipeline By Therapeutic Class, H2 2011
ViroMed Co., Ltd. – Pipeline By Route of Administration, H2 2011 Skip to top